GB0901837D0 - Cancer diagnosis and treatment - Google Patents

Cancer diagnosis and treatment

Info

Publication number
GB0901837D0
GB0901837D0 GBGB0901837.5A GB0901837A GB0901837D0 GB 0901837 D0 GB0901837 D0 GB 0901837D0 GB 0901837 A GB0901837 A GB 0901837A GB 0901837 D0 GB0901837 D0 GB 0901837D0
Authority
GB
United Kingdom
Prior art keywords
treatment
cancer diagnosis
diagnosis
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0901837.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cizzle Biotechnology Ltd
Original Assignee
Cizzle Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cizzle Biotechnology Ltd filed Critical Cizzle Biotechnology Ltd
Priority to GBGB0901837.5A priority Critical patent/GB0901837D0/en
Publication of GB0901837D0 publication Critical patent/GB0901837D0/en
Priority to EP10706706A priority patent/EP2393498A1/en
Priority to PCT/GB2010/000204 priority patent/WO2010089559A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
GBGB0901837.5A 2009-02-05 2009-02-05 Cancer diagnosis and treatment Ceased GB0901837D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0901837.5A GB0901837D0 (en) 2009-02-05 2009-02-05 Cancer diagnosis and treatment
EP10706706A EP2393498A1 (en) 2009-02-05 2010-02-05 Cancer diagnosis and treatment
PCT/GB2010/000204 WO2010089559A1 (en) 2009-02-05 2010-02-05 Cancer diagnosis and treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0901837.5A GB0901837D0 (en) 2009-02-05 2009-02-05 Cancer diagnosis and treatment

Publications (1)

Publication Number Publication Date
GB0901837D0 true GB0901837D0 (en) 2009-03-11

Family

ID=40469583

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0901837.5A Ceased GB0901837D0 (en) 2009-02-05 2009-02-05 Cancer diagnosis and treatment

Country Status (3)

Country Link
EP (1) EP2393498A1 (en)
GB (1) GB0901837D0 (en)
WO (1) WO2010089559A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601212A1 (en) * 2010-08-04 2013-06-12 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of
GB201518466D0 (en) * 2015-10-19 2015-12-02 Cizzle Biotechnology Ltd Use
WO2019079914A1 (en) * 2017-10-23 2019-05-02 蔡胜和 Anti-ciz1 antibody
CN108796083B (en) * 2018-06-25 2021-03-19 山东大学 Application of CIZ1 as molecular marker for diagnosing and treating tongue hemangioma
CN114410780A (en) * 2021-12-30 2022-04-29 武汉科技大学 Application of KIF4A in diagnosis, prognosis and treatment of breast cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228337D0 (en) * 2002-12-05 2003-01-08 Yorkshire Cancer Res Campaign Replication protein

Also Published As

Publication number Publication date
WO2010089559A1 (en) 2010-08-12
EP2393498A1 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
GB0922085D0 (en) Cancer diagnosis and treatment
HK1175476A1 (en) Cancer treatment
IL218575A0 (en) Treatment of cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
EP2629736A4 (en) Tissue treatment
EP2332459A4 (en) Medical treatment system
EP2412297A4 (en) Cover type endoscope for treatment and cover for endoscope
EP2606349A4 (en) Cancer diagnostic and cancer therapeutic
EP2412328A4 (en) Medical treatment device
EP2340851A4 (en) Diagnosis method and therapeutic method for cancer
IL214133A0 (en) Skin treatment
GB0918392D0 (en) Diagnostic and therapeutic methods
IL240560A0 (en) Compositions and methods for the diagnosis and treatment of tumor
IL221035A0 (en) Cancer diagnosis and imaging
IL222958A0 (en) Cancer treatment
GB0900599D0 (en) Treatment
EP2420515A4 (en) Diagnosis and treatment of cancer using anti-tmprss11e antibody
GB0901837D0 (en) Cancer diagnosis and treatment
EP2361317A4 (en) Use of eif3m for the diagnosis and treatment of cancer
PT2630475T (en) Diagnostic method and treatment
EP2438167A4 (en) Therapeutic and diagnostic molecules
ZA201203286B (en) Therapeutic and diagnostic applications against trypanosomosis
EP2403341A4 (en) Lung cancer treatment
EP2384370A4 (en) Use of id4 for diagnosis and treatment of cancer
GB0916686D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)